Skip to main content

Advertisement

Table 4 TP53-positive group. Cumulated odds of achieving platinum highly sensitive response with the two therapies in patients with various combinations of residual tumor size and tumor grade (the odds are based on multivariate models, table 2).

From: TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: A non-randomized retrospective study

Residual tumor (RT) Tumor grade Cumulated odds PC/PAC Cumulated odds TP
0 2 1 10.73
≤2 cm 2 1 10.73
>2 cm 2 1 63.84
0 3 1 1.18
≤2 cm 3 1 1.18
>2 cm 3 1 7.02
0 4 1 0.43
≤2 cm 4 1 0.43
>2 cm 4 1 2.55
  1. The odds are higher for taxane-platinum therapy in all patients with residual tumor >2 cm or with grade 2 tumors. The odds are higher for platinum-based therapy in patients with grade 4 tumors and residual tumor 0–≤2 cm (bold). For other patients the odds for the two chemotheraputic regimens are similar.